Navigation Links
Nephrologists and Non-Nephrologists Alike Report Increased Attention on Chronic Kidney Disease
Date:5/23/2008

EXTON, Pa., May 23 /PRNewswire/ -- BioTrends Research Group, Inc. released a Special Report: "Referrals in Nephrology," providing insight into the referral patterns and co-management of patients with Chronic Kidney Disease (pre-dialysis) from the perspective of Nephrologists, Cardiologists, Endocrinologists, and Primary Care Physicians. The newly released syndicated report offers a comprehensive view, based on qualitative interviews with 40 physicians and quantitative feedback from close to 300 physicians, about awareness of CKD, triggers for referral, knowledge of and treatment with therapies for renal anemia, secondary hyperparathyroidism, hyperphosphatemia, and hypertension. It also includes 10 interviews with Managed Care Organizations to determine their involvement in referrals to Nephrologists and control mechanisms for various classes and brands of medications.

According to the study, awareness of CKD seems to be growing among all specialties. Although there is high agreement around the benefits of early screening for CKD, there is relatively low familiarity with the National Kidney Foundation's CKD Staging Classification and virtually no familiarity with the Kidney Early Evaluation Program (KEEP), a program designed to raise awareness, educate, provide physician referrals, and ultimately delay disease progression. While Endocrinologists and Cardiologists do refer patients with CKD to Nephrologists, the majority of referrals come from PCPs. Managed care does not play a role in when patients are referred to Nephrologists.

In terms of treatment of CKD patients, while all specialties are familiar with and comfortable prescribing ACEs and ARBs, there are differences between specialties when it comes to phosphate binders, PTH modifiers, ESAs, and IV Iron. Cardiologists are least interested in managing renal issues in patients with CKD. Some of the differences in level of involvement are specialty driven, whereas others seem to be based on practice setting (urban/rural/suburban) and practice type (solo/group/multi-specialty). Pharmaceutical companies appear to be taking different approaches to reaching these non-Nephrology physicians involved in the management of CKD patients. Some companies are targeting them directly while others are limiting promotion to Nephrologists.

About BioTrends Research Group, Inc.

BioTrends Research Group, Inc. (http://www.bio-trends.com) provides syndicated and custom market research to pharmaceutical manufacturers competing in clinically evolving, specialty pharmaceutical markets. For information on BioTrends publications and research capabilities, please contact Jennifer Robinson at (610) 363-3872 or jrobinson@bio-trends.com.

All company, brand, or product names contained in this document may be trademarks of their respective holders.


'/>"/>
SOURCE BioTrends Research Group, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Awareness of Genzymes Renvela(R) (Sevelamer Carbonate) is High, Although Uptake of this New Phosphate Binding Agent has Been Slower than Nephrologists and Renal Dietitians Initially Expected
2. BioTrends Releases Two Publications - TreatmentTrends(TM): Nephrologists and TreatmentTrends(TM): Renal Dietitians - Highlighting Market Trends for Renal Anemia, Hyperphosphatemia, and Secondary Hyperparathyroidism
3. Rosetta Genomics Reports First Quarter 2008 Financial Results
4. Genetic Engineering and Biotechnology News (GEN) Reports on Mass Spec in Drug Discovery
5. Advance Nanotech Reports First Quarter 2008 Financial Results
6. Senesco Technologies Reports Third Quarter Fiscal 2008 Financial Results
7. Senetek PLC Reports First Quarter 2008 Financial Results
8. New Study Reports That Ablative Therapy With HALO360 Device Effectively Treats Highest-Risk Category of Barretts Esophagus
9. China Biologic Products Reports First Quarter 2008 Results
10. Escalon(R) Reports Third Quarter Fiscal 2008 Results
11. Cadus Reports First Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... SAN JOSE, Calif. , Feb. 23, 2017 ... an exclusive license for two key immunotherapy technologies ... The first technology provides a method to monitor ... therapy such as PD-L1 and CTLA-4.  The second ... detect if a patient is likely to have ...
(Date:2/23/2017)... ... February 23, 2017 , ... Brain Sentinel, ... begin marketing the SPEAC® System, the Brain Sentinel® Seizure Monitoring and Alerting System. ... healthcare facilities during periods of rest. A lightweight, non-invasive monitor is placed on ...
(Date:2/23/2017)... NC (PRWEB) , ... February 23, 2017 , ... ... to announce a new partnership with Compass Research . GGI's mission is to ... a vaccine to a child in need in honor of each clinical trial volunteer. ...
(Date:2/23/2017)... ... February 22, 2017 , ... Seventy-one members of ... Fellows of the Society this year, the Fellows Committee has announced. The honor ... optics, photonics, and imaging as well as their service to the Society and ...
Breaking Biology Technology:
(Date:2/16/2017)... , Feb. 16, 2017  Genos, a ... announced that it has received Laboratory Accreditation from ... Accreditation is presented to laboratories that meet stringent ... demonstrate scientifically rigorous processes. "Genos is ... in laboratory practices. We,re honored to be receiving ...
(Date:2/10/2017)... 2017 Research and Markets has ... Medicine - Scientific and Commercial Aspects" to their offering. ... ... integrated with therapy for selection of treatment as well for ... prevention of disease in modern medicine. Biochip/microarray technologies and next ...
(Date:2/8/2017)... , Feb. 7, 2017 Report Highlights ... The global synthetic-biology ... $11.4 billion by 2021, growing at a compound annual growth ... An overview of the global markets for synthetic biology. - ... for 2016, and projections of compound annual growth rates (CAGRs) ...
Breaking Biology News(10 mins):